What Is PCAC? The FDA's Pharmacy Compounding Advisory Committee

What PCAC is and what it does

PCAC is the Pharmacy Compounding Advisory Committee, a standing federal advisory committee chartered to give the FDA outside expertise on compounding questions. Its most consequential job is helping the agency decide which bulk drug substances — raw active pharmaceutical ingredients, explained in what a bulk drug substance means — may be used in pharmacy compounding when they lack a monograph or an approved-drug link. In practice, that means PCAC is a key voice in building and maintaining the 503A bulks list.

The committee brings together experts — typically pharmacists, physicians, toxicologists, and other scientists, plus consumer and industry representatives — to review the evidence on a nominated substance. They examine its safety data, the quality of its characterization, historical use, and whether a real compounding need exists. Then they discuss it in an open session and vote on a recommendation to the FDA. This all happens inside the traditional, patient-specific compounding regime defined by Section 503A, as opposed to the outsourcing-facility rules of Section 503B.

How PCAC fits into the 503A bulks-list process

When someone nominates a bulk substance for the 503A list, the FDA does an initial review and places it, on an interim basis, into one of two buckets. Category 1 substances may be used in compounding while the FDA finishes its evaluation. Category 2 substances are those for which the agency has identified significant safety concerns and says should not be used in compounding during review. PCAC's role is to examine the evidence for these nominations and advise the FDA on where a substance belongs.

1. A bulk substance is nominated for the 503A bulks list.
2. The FDA performs an initial review and assigns an interim category (1 or 2).
3. PCAC reviews the evidence in a public meeting and votes on a recommendation.
4. The FDA considers the recommendation but makes the final determination — the vote alone changes nothing.

Because PCAC meetings are public, they are one of the few windows into the FDA's reasoning on peptides. Meeting materials, briefing documents, and the vote itself are published, and there is an open public comment period. That transparency is why coverage of committee meetings — like our FDA advisory committee vote explainer — leans so heavily on the committee record.

Why PCAC matters for peptides in 2026

Several research peptides — including BPC-157, TB-500 (thymosin beta-4), Ipamorelin, CJC-1295, and GHK-Cu — were placed in Category 2, which is the specific mechanism that keeps them out of legitimate compounding pharmacies. Whether that changes depends in part on how the FDA weighs new evidence, and PCAC is the forum where much of that weighing happens in the open. To see how the category rule blocks a single peptide in detail, read the BPC-157 research profile alongside our compounding explainers.

On April 15, 2026, the FDA announced it would convene a committee to reconsider its restrictions on several compounding peptides, with a meeting scheduled for July 23, 2026. We track that event in the FDA peptide update for July 2026. The important framing is the same one that applies to every PCAC vote: even a favorable recommendation is a step in a process, not a decision, and it would take further FDA action — likely months — before anything about a peptide's status actually changed.